Navigation Links
New understanding of why anti-cancer therapy stops working at a specific stage
Date:6/24/2013

Jerusalem, June 23, 2013 Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells. Their work could lead to new insights into overcoming this impasse.

The problematic therapy investigated involves suppression of the protein mTOR (mammalian target Of Rapamycin). MTOR plays an important role in regulating how cells process molecular signals from their environment, and it is observed as strongly activated in many solid cancers.

Drug-induced suppression of mTOR has until now shown success in causing the death of cancer cells in the outer layers of cancerous tumors, but has been disappointing in clinical trials in dealing with the core of those tumors.

Reduced oxygen supply -- hypoxia -- is a near-universal feature of solid tumors that can alter how tumors respond to therapies. It was known that the behavior of mTOR signaling is influenced and altered by the condition of hypoxia, but the mechanism to explain this was unknown.

A research team, which included Prof. Emeritus Raphael D. Levine of the Institute of Chemistry at the Hebrew University of Jerusalem and researchers from the California Institute of Technology and the David Geffen School of Medicine at UCLA, investigated whether the influence of hypoxia on mTOR signaling in model brain cancer systems could explain the poor performance of mTOR drugs. Their work appeared in a recent article in the Proceedings of the National Academy of Sciences (PNAS) in the US.

For their investigation, they employed a new microchip technology that allowed them to measure the mTOR protein signaling network in individual cancer cells, and they interpreted the results using a new set of theoretical tools derived from the physical sciences. The combined approach permitted the simplification of an otherwise complex biological system.

They found that at a particular level of oxygen starvation (hypoxia) that is common in solid tumors, the mTOR signaling network switches between two sets of properties. At the switching point, the theoretical models predicted that mTOR would be intrinsically unresponsive to drugging.

Furthermore, the combined experiment and theory results indicated that the switch could be interpreted as a type of phase transition, which has not been previously observed in biological systems.

This phase transition is the point of the switch between the two signaling networks and happens very abruptly. The change in signaling means that the body of cells studied no longer responds in the way it did before. In the case of the tumor, the "drugging" of the mTOR ceases, meaning that the tumor is no longer inhibited.

These results have several implications. First, they may explain the poor clinical performance of mTOR inhibitors. Second, they indicate that certain complex biological behaviors, which often confound scientists who are seeking to find effective therapies for human diseases, may be understood by the effective application of experimental and theoretical tools derived from the physical sciences.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huni.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. Lumositys big data provides new approach to understanding human cognition
2. Researchers gain new molecular-level understanding of the brains recovery after stroke
3. United Benefit Advisors Offers Employee Guide to Understanding PPACA
4. Biolog’s Phenotype MicroArray Technology Unlocks Critical Clue in Understanding Autism
5. Tools for better understanding breast cancer stem cells
6. OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role
7. Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases
8. Study brings greater understanding of tumor growth mechanism
9. Such a Great Date, Why Hasn't He/She Called Yet? Dr. Bonnie Provides Tips on Making it Thur the Dating Stages and Understanding the Opposite Sex
10. Sherri Gastelum and Platinum Tax Defenders Offer 5 Tips on Understanding Health Care Tax Issues from the Affordable Care Act
11. Liver disease: Understanding it will enable the provision of better treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical ... high performance apparel for healthcare and other demanding applications, ... Chief Executive Officer. He replaces Dale Pfost , ... Chairman. Mr. Bold is also joining Vestagen,s Board of ... new class of active barrier technologies that combines fluid ...
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... -- Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko ... as president, Americas Operations, for Astellas US LLC, with ... South America , effective April 1, 2016.  Robinson previously ... in the United States -- a ... , who is retiring in June 2016.  --> ...
Breaking Medicine Technology: